Matches in SemOpenAlex for { <https://semopenalex.org/work/W1820238416> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W1820238416 endingPage "iv369" @default.
- W1820238416 startingPage "iv369" @default.
- W1820238416 abstract "ABSTRACT Aim: IPGG is a yeast-derived b-glucan that primes innate immune cells to kill monoclonal antibody-targeted cancer cells via complement receptor 3 (CR3). Subjects with anti-beta glucan antibodies (ABA) levels conducive to IPGG binding to CR3 are considered “biomarker positive” (BM+). We have previously reported significant improvements in objective responses with IPGG in combination with cetuximab, carboplatin and paclitaxel in patients (pts) with advanced NSCLC. Herein, we present the secondary endpoints of the clinical trial. Methods: Pts with Stage IV NSCLC received cetuximab (CET) 250 mg/m2 following initial 400 mg/m2 loading dose) without (Control, N = 30) or with IPGG 4mg/kg (IPGG, N = 60) on Days 1, 8 and 15 of each 3-week treatment cycle, and carboplatin (AUC 6) + paclitaxel (200 mg/m2) on Day 2 for the first 4 to 6 cycles. Pts achieving radiographic stable disease or tumor response (modified RECIST 1.0) received CET or CET/IPGG maintenance treatment. The primary endpoint was objective response rate. Secondary endpoints included disease control rate (DCR: CR + PR + SD), time to progression (TTP), overall survival (OS) and safety. Results: Best overall response (control vs IPGG) was PR in 23.1% vs 47.8% (p = 0.048), SD in 53.8% vs 30.4%, and PD in 23.1% vs 21.7%, respectively; DCR was 76.9% vs 78.3%, respectively (p = NS). ORR was 66.7% with IPGG in BM+ pts (p = 0.009 vs. Control) and 38.7% in the BM - group (p = NS vs. Control). Median TTP was 4.4 mo vs 4.3 mo respectively in the overall population and 5.6 mo in BM+ pts receiving IPGG (p = NS). OS was 11.3 mo vs 12.4 mo overall (p = NS), and 16.7 mo in BM+ pts vs. 9.4 mo in BM- pts receiving IPGG (p = 0.133). All subjects had at least one adverse event; grade III/IV adverse events occurred in 86.2% vs 78.0% of control vs. IPGG-treated pts. Conclusions: In patients with stage IV NSCLC receiving combination therapy with carboplatin, paclitaxel and CET, IPGG was well tolerated, improved objective responses and prolonged OS in BM+ pts. Disclosure: N. Bose, M.L. Patchen, J. Lowe, P. Mattson, M. Gargano, R.D. Huhn and A. Braun: Employee of Biothera, Inc.All other authors have declared no conflicts of interest." @default.
- W1820238416 created "2016-06-24" @default.
- W1820238416 creator A5005474411 @default.
- W1820238416 creator A5008532485 @default.
- W1820238416 creator A5008633109 @default.
- W1820238416 creator A5030114680 @default.
- W1820238416 creator A5034878356 @default.
- W1820238416 creator A5036720043 @default.
- W1820238416 creator A5044399684 @default.
- W1820238416 creator A5045517706 @default.
- W1820238416 creator A5049904099 @default.
- W1820238416 creator A5080892315 @default.
- W1820238416 creator A5091537617 @default.
- W1820238416 date "2014-09-01" @default.
- W1820238416 modified "2023-09-28" @default.
- W1820238416 title "Chemoimmunotherapy of Advanced Non-Small Cell Lung Cancer (Nsclc) with Imprime Pgg (Ipgg) in Combination with Cetuximab, Carboplatin and Paclitaxel–Analysis of Secondary Endpoints of a Multicenter, Randomized Phase 2 Trial" @default.
- W1820238416 doi "https://doi.org/10.1093/annonc/mdu342.24" @default.
- W1820238416 hasPublicationYear "2014" @default.
- W1820238416 type Work @default.
- W1820238416 sameAs 1820238416 @default.
- W1820238416 citedByCount "1" @default.
- W1820238416 countsByYear W18202384162016 @default.
- W1820238416 crossrefType "journal-article" @default.
- W1820238416 hasAuthorship W1820238416A5005474411 @default.
- W1820238416 hasAuthorship W1820238416A5008532485 @default.
- W1820238416 hasAuthorship W1820238416A5008633109 @default.
- W1820238416 hasAuthorship W1820238416A5030114680 @default.
- W1820238416 hasAuthorship W1820238416A5034878356 @default.
- W1820238416 hasAuthorship W1820238416A5036720043 @default.
- W1820238416 hasAuthorship W1820238416A5044399684 @default.
- W1820238416 hasAuthorship W1820238416A5045517706 @default.
- W1820238416 hasAuthorship W1820238416A5049904099 @default.
- W1820238416 hasAuthorship W1820238416A5080892315 @default.
- W1820238416 hasAuthorship W1820238416A5091537617 @default.
- W1820238416 hasConcept C121608353 @default.
- W1820238416 hasConcept C126322002 @default.
- W1820238416 hasConcept C126894567 @default.
- W1820238416 hasConcept C143998085 @default.
- W1820238416 hasConcept C203092338 @default.
- W1820238416 hasConcept C2776256026 @default.
- W1820238416 hasConcept C2776694085 @default.
- W1820238416 hasConcept C2777063308 @default.
- W1820238416 hasConcept C2777292972 @default.
- W1820238416 hasConcept C2778239845 @default.
- W1820238416 hasConcept C2779984678 @default.
- W1820238416 hasConcept C2779998722 @default.
- W1820238416 hasConcept C2781451048 @default.
- W1820238416 hasConcept C31760486 @default.
- W1820238416 hasConcept C526805850 @default.
- W1820238416 hasConcept C535046627 @default.
- W1820238416 hasConcept C71924100 @default.
- W1820238416 hasConcept C90924648 @default.
- W1820238416 hasConceptScore W1820238416C121608353 @default.
- W1820238416 hasConceptScore W1820238416C126322002 @default.
- W1820238416 hasConceptScore W1820238416C126894567 @default.
- W1820238416 hasConceptScore W1820238416C143998085 @default.
- W1820238416 hasConceptScore W1820238416C203092338 @default.
- W1820238416 hasConceptScore W1820238416C2776256026 @default.
- W1820238416 hasConceptScore W1820238416C2776694085 @default.
- W1820238416 hasConceptScore W1820238416C2777063308 @default.
- W1820238416 hasConceptScore W1820238416C2777292972 @default.
- W1820238416 hasConceptScore W1820238416C2778239845 @default.
- W1820238416 hasConceptScore W1820238416C2779984678 @default.
- W1820238416 hasConceptScore W1820238416C2779998722 @default.
- W1820238416 hasConceptScore W1820238416C2781451048 @default.
- W1820238416 hasConceptScore W1820238416C31760486 @default.
- W1820238416 hasConceptScore W1820238416C526805850 @default.
- W1820238416 hasConceptScore W1820238416C535046627 @default.
- W1820238416 hasConceptScore W1820238416C71924100 @default.
- W1820238416 hasConceptScore W1820238416C90924648 @default.
- W1820238416 hasLocation W18202384161 @default.
- W1820238416 hasOpenAccess W1820238416 @default.
- W1820238416 hasPrimaryLocation W18202384161 @default.
- W1820238416 hasVolume "25" @default.
- W1820238416 isParatext "false" @default.
- W1820238416 isRetracted "false" @default.
- W1820238416 magId "1820238416" @default.
- W1820238416 workType "article" @default.